NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells

Leukemia

Volumn 24, Issue 4, 2010, Pages 860-861

  Hackanson, B ^a   Abdelkarim, M ^a   Jansen, J H ^b   Lubbert M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; GENOMIC DNA; HYBRID PROTEIN; PROTEIN SON; TRANSCRIPTION FACTOR RUNX1 ETO FUSION PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; CHROMOSOME TRANSLOCATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LETTER; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SOMATIC MUTATION;

EID: 77950959049     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.291     Document Type: Letter

References (11)

1. Fröhling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005; 23: 6285-6295.
2. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115-136.
3. Liu Y, Chen W, Gaudet J, Cheney MD, Roudaia L, Cierpicki T et al. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Cancer Cell 2007; 11: 483-497.
4. Ahn EY, Yan M, Malakhova OA, Lo MC, Boyapati A, Ommen HB et al. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proc Natl Acad Sci USA 2008; 105: 17103-17108.
5. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002; 1: 63-74.
6. Akagi T, Shih LY, Ogawa S, Gerss J, Moore SR, Schreck R et al. Single nucleotide polymorphism genomic arrays analysis of t(8;21) acute myeloid leukemia cells. Haematologica 2009; 94: 1301-1306.
7. Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005; 115: 2159-2168.
8. Schnittger S, Bacher U, Kern W, Haferlach C, Haferlach T. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/AML1-ETO-positive AML. Leukemia 2007; 21: 183-184.
9. Beghini A, Ripamonti CB, Cairoli R, Cazzaniga G, Colapietro P, Elice F et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004; 89: 920-925.
10. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904-3911. (Pubitemid 46630738)
11. Müller AM, Duque J, Shizuru JA, Lübbert M. Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene 2008; 27: 5759-5773.